Orchestra BioMed Holdings Investor Relations Material

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating the development and commercialization of high-impact medical technologies. The company operates through a partnership-enabled business model, collaborating with leading medical device companies to bring its innovations to market. Its key product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT), which is designed to treat hypertension in patients with pacemakers, and Virtue Sirolimus AngioInfusion Balloon (SAB), intended for the treatment of atherosclerotic artery disease. Orchestra BioMed has strategic partnerships with companies like Medtronic and Terumo Corporation to advance the development and global commercialization of these products. The company is headquartered in New Hope, Pennsylvania, and its shares are listed on the Nasdaq.